ACT-389949 - 98%, high purity , CAS No.1258417-54-7, Agonist of FPR2/ALX

Item Number
A412452
Grouped product items
SKUSizeAvailabilityPrice Qty
A412452-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$259.90
A412452-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$399.90
A412452-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$119.90
A412452-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,035.90

ADC Cytotoxin

Basic Description

SynonymsN-(2-{[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl}-2H-1,2,3-triazol-4-yl)-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide | N-[2-[[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide | A
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsACT-389949 is a potent, selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) with EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for inflammatory disorders.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeAGONIST
Mechanism of actionAgonist of FPR2/ALX
Product Description

Information

ACT-389949 is a potent, selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) with EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for inflammatory disorders.

Associated Targets(Human)

FPR2 Tchem N-formyl peptide receptor 2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name N-[2-[[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide
INCHI InChI=1S/C20H18F2N6O3/c1-11-5-4-6-13(7-11)18-17(24-12(2)31-18)19(29)26-15-8-23-28(27-15)9-16-25-14(10-30-16)20(3,21)22/h4-8,10H,9H2,1-3H3,(H,26,27,29)
InChi Key PBTWPEDVIMHJEO-UHFFFAOYSA-N
Canonical SMILES CC1=CC(=CC=C1)C2=C(N=C(O2)C)C(=O)NC3=NN(N=C3)CC4=NC(=CO4)C(C)(F)F
Isomeric SMILES CC1=CC(=CC=C1)C2=C(N=C(O2)C)C(=O)NC3=NN(N=C3)CC4=NC(=CO4)C(C)(F)F
Alternate CAS 1258417-54-7
PubChem CID 49834265
MeSH Entry Terms 2-methyl-5-m-tolyloxazole-4-carboxylic acid (2-(4-(1,1-difluoroethyl)oxazol-2-ylmethyl)-2H-(1,2,3)triazol-4-yl)amide;ACT-389949
Molecular Weight 428.4

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

5 results found

Lot NumberCertificate TypeDateItem
A2426242Certificate of AnalysisDec 25, 2023 A412452
A2426243Certificate of AnalysisDec 25, 2023 A412452
A2426244Certificate of AnalysisDec 25, 2023 A412452
A2426245Certificate of AnalysisDec 25, 2023 A412452
A2426247Certificate of AnalysisDec 25, 2023 A412452

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro Ethanol: mg/mL    

Related Documents

References

1. Stalder AK, Lott D, Strasser DS, Cruz HG, Krause A, Groenen PM, Dingemanse J.  (2017)  Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949..  Br J Clin Pharmacol,  83  (3): (476-486).  [PMID:27730665] [10.1021/op500134e]

Solution Calculators